Metformin alleviates bevacizumab-induced vascular endothelial injury in mice through growth differentiation factor ۱۵ upregulation

Publish Year: 1403
نوع سند: مقاله ژورنالی
زبان: English
View: 47

This Paper With 9 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJBMS-27-3_011

تاریخ نمایه سازی: 8 بهمن 1402

Abstract:

Objective(s): Bevacizumab is a commonly used anticancer drug in clinical practice, but it often leads to adverse reactions such as vascular endothelial damage, hypertension, arterial and venous thrombosis, and bleeding. This study investigated the protective effects of metformin against bevacizumab-induced vascular injury in a mouse model and examined the possible involvement of GDF۱۵/PI۳K/AKT/FOXO/PPARγ signaling in the effects.Materials and Methods: C۵۷ male mice were purchased. To investigate metformin, the mice were assigned to the saline, bevacizumab (۱۵ mg every ۳ days), metformin (۱۲۰۰ mg/day), and bevacizumab+metformin groups. To investigate GDF۱۵, the mice were assigned to the siNC+bevacizumab, siNC+bevacizumab+metformin, siGDF۱۵+bevacizumab, and siGDF۱۵+bevacizumab+metformin groups. Histological staining was used to evaluate vascular injury. Flow cytometry was used to evaluate apoptosis. ELISA was used to measure plasma endothelial injury markers and proinflammatory cytokines. qRT-PCR and western blot were used to determine the expression of GDF۱۵ and PI۳K/AKT/FOXO/PPARγ in aortic tissues.Results: Metformin alleviated bevacizumab-induced abdominal aortic injury, endothelial cell apoptosis, and systemic inflammation in mice (all P<۰.۰۵). Metformin up-regulated GDF۱۵ expression and PI۳K/AKT/FOXO/PPARγ signaling in the abdominal aorta of mice treated with bevacizumab (all P<۰.۰۵). siGDF۱۵ abolished the vascular protective and anti-inflammatory effects of metformin (all P<۰.۰۵). siGDF۱۵ suppressed PI۳K/AKT/FOXO/PPARγ signaling in the abdominal aorta of mice treated with bevacizumab (all P<۰.۰۵).Conclusion: Metformin attenuates bevacizumab-induced vascular endothelial injury, apoptosis, and systemic inflammation by activating GDF۱۵/PI۳K/AKT/FOXO/PPARγ signaling.

Authors

Liqiang Chen

Department of Cardiovascular, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

Yajuan Yin

Department of Cardiovascular, The First Hospital of Hebei Medical University, Shijiazhuang, China

Chunmiao Liu

Department of Obstetrics,The Fourth Hospital of Shijiazhuang,Shijiazhuang, China

Junying Liu

Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

Mingqi Zheng

Department of Cardiovascular, The First Hospital of Hebei Medical University, Shijiazhuang, China

Yida Tang

Department of Cardiology, Peking University Third Hospital, ۴۹ Huayuanbei Road, Haidian District, Beijing ۱۰۰۱۹۱, China

Qing Yang

Department of Cardiology, Tianjin Medical University General Hospital, ۱۵۴ Anshan Road, Heping District, Tianjin ۳۰۰۰۵۲, China

Jing Liu

Department of Cardiovascular, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

Fan Chen

Department of Cardiovascular, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

Lanbo Liu

Department of Cardiovascular, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

Gang Liu

Department of Cardiovascular, The First Hospital of Hebei Medical University, Shijiazhuang, China

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Wang B, He F, Hu Y, Wang Q, Wang D, ...
  • Nojiri T, Inoue M, Takeuchi Y, Maeda H, Shintani Y, ...
  • Kozower BD, Sheng S, O’Brien SM, Liptay MJ, Lau CL, ...
  • Abdelsalam M, Abu-Hegazy M, El-Hadaad HA, Wahba H, Egila H, ...
  • Ansari MJ, Bokov D, Markov A, Jalil AT, Shalaby MN, ...
  • Teleanu RI, Chircov C, Grumezescu AM, Teleanu DM. Tumor angiogenesis ...
  • Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. ...
  • Cao Y, Langer R, Ferrara N. Targeting angiogenesis in oncology, ...
  • Small HY, Montezano AC, Rios FJ, Savoia C, Touyz RM. ...
  • Jang S, Zheng C, Tsai HT, Fu AZ, Barac A, ...
  • Gimbrone MA, Jr., Garcia-Cardena G. Endothelial cell dysfunction and the ...
  • Sun HJ, Wu ZY, Nie XW, Bian JS. Role of ...
  • Nakaya A, Kurata T, Yokoi T, Iwamoto S, Torii Y, ...
  • Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. ...
  • Randall LM, Monk BJ. Bevacizumab toxicities and their management in ...
  • Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, ...
  • Totzeck M, Mincu RI, Rassaf T. Cardiovascular adverse events in ...
  • Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, ...
  • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, ...
  • Roumie CL, Chipman J, Min JY, Hackstadt AJ, Hung AM, ...
  • Luo F, Das A, Chen J, Wu P, Li X, ...
  • Saraei P, Asadi I, Kakar MA, Moradi-Kor N. The beneficial ...
  • Lord SR, Harris AL. Is it still worth pursuing the ...
  • Salvatore T, Pafundi PC, Galiero R, Rinaldi L, Caturano A, ...
  • Fan Y, Cheng H, Liu Y, Liu S, Lowe S, ...
  • Marrone KA, Zhou X, Forde PM, Purtell M, Brahmer JR, ...
  • Vanhoutte PM, Shimokawa H, Feletou M, Tang EH. Endothelial dysfunction ...
  • Johnen H, Kuffner T, Brown DA, Wu BJ, Stocker R, ...
  • Ha G, De Torres F, Arouche N, Benzoubir N, Ferratge ...
  • Gerstein HC, Pare G, Hess S, Ford RJ, Sjaarda J, ...
  • Day EA, Ford RJ, Smith BK, Mohammadi-Shemirani P, Morrow MR, ...
  • Chen L, Yin Y, Liu G. Metformin alleviates bevacizumab-induced vascular ...
  • Soraya H, Khorrami A, Garjani A, Maleki-Dizaji N, Garjani A. ...
  • Quaile MP, Melich DH, Jordan HL, Nold JB, Chism JP, ...
  • Wu HR. Effect of recombinant human VEGF_(۱۶۵)b protein and bevacizumab ...
  • Zhang J. Time window of bevacizumab-induced tumour vascular normalisation and ...
  • Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, ...
  • Costa R, Carneiro A, Rocha A, Pirraco A, Falcao M, ...
  • Bota M, Fischer-Fodor E, Bochis OV, Cenariu M, Popa G, ...
  • El-Hajjar L, Jalaleddine N, Shaito A, Zibara K, Kazan JM, ...
  • Hattori Y, Suzuki K, Hattori S, Kasai K. Metformin inhibits ...
  • Hung CH, Chan SH, Chu PM, Lin HC, Tsai KL. ...
  • Li X, Kover KL, Heruth DP, Watkins DJ, Moore WV, ...
  • Yang Y, Dong R, Hu D, Chen Z, Fu M, ...
  • Niu C, Chen Z, Kim KT, Sun J, Xue M, ...
  • Li Y, Gappy S, Liu X, Sassalos T, Zhou T, ...
  • Indraccolo S, Randon G, Zulato E, Nardin M, Aliberti C, ...
  • Silvestre-Roig C, Braster Q, Ortega-Gomez A, Soehnlein O. Neutrophils as ...
  • Li J, Yang L, Qin W, Zhang G, Yuan J, ...
  • Coll AP, Chen M, Taskar P, Rimmington D, Patel S, ...
  • Klein AB, Nicolaisen TS, Johann K, Fritzen AM, Mathiesen CV, ...
  • Li A, Zhao F, Zhao Y, Liu H, Wang Z. ...
  • Li S, Ma YM, Zheng PS, Zhang P. GDF۱۵ promotes ...
  • Keating GM. Bevacizumab: A review of its use in advanced ...
  • Soraya H, Esfahanian N, Shakiba Y, Ghazi-Khansari M, Nikbin B, ...
  • نمایش کامل مراجع